{"ticker": {"uuid": "1772476d-3e9d-4598-bb50-6351ded7a204", "symbol": "GILD", "name": "Gilead Sciences, Inc.", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Gilead (GILD) Stock Could Still Trade At A Discount Following Its 127% Run", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-22T08:27:46+00:00", "published_display": "22 Jul 2026 08:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead sets Aug. 4 webcast to discuss second-quarter results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOcTY5bXFhQVlYY1ZzSms0SjBvR19UT3hnMHdsQ2piN0EySDYwdTl5ekUtdEJoV3JaZTRsMlRRODloMk5YMVVnR21PTFNoVEY2V251clJsOHk0QmlDNmk1VFd4YTZ5MHowZ29sUl8tMEhQd0RlMmpTcDFRcUJkRkVYdWJ1NDdra3FfaXZlQ1RYN0k2cVhhallHZUQ0enV5cXZaNXZiVWVzRTJaS205OXMtLWJ6cFdIcTRrNm93TGhzUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T20:05:00+00:00", "published_display": "21 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences' Quarterly Earnings Preview: What You Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUUVFdUhNc042MDJaendBLWNVOTk3enR6RUd3cXYyREpoT1ZrRVNOX3F2MGtBbnhabG4ydkFpaFZLMkV1WW4yM1JMdVhfdmJCLThiVTA2dDU2THM3QmcxanpqQXJWNDMyVjdXQlZ4VXJrTzdLbUJFOTMyZWRmMGhEY1BUZXpBRVlZOF9DdUZsUzc0cTdJVmk3TE1MTENMSm9v?oc=5", "source_name": "inkl", "published_at": "2026-07-21T12:56:06+00:00", "published_display": "21 Jul 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxObUJabGVPbXJTRnMycU9vSmp1Q0RCZExIZUNPbUhMbno0QW1tTllEYnNoOU1KS3k5TGFNYlc0RU5EMlRYMGpKbFRFUHdnQzFaX0prLWxJTHduRldEYnkzeDRUd25DZjRlS3o1Z19JcElPemNQamNTSl9FRDdEUFo2Y0tqQlNDaGFJWS16OUZQVjJyeWZncjlOM1gxNUpSQnJuMkNEc0JvdDRndmVZTThoLXpNOXE3ejNIb1dV?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T21:35:27+00:00", "published_display": "16 Jul 2026 21:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZFYxNFltWHNNWXR0X0djdnRuVmRIV1IxLVdpRUpBOUZkZUZkNkkzQUJpZVAyVXFmNy1sRVVBdnpQWDlrTlNyZXZiaElvOHZuYjFuNHZnM1V0SUFqal9VNTNUX0kwZWx3b0JiOF9HVUpSS2J4WXZES3RWd0dOVHlhT3l4U3AxbVZIWWppeXVCUlhhYTZLUkpLV3V5SkY5UERINnFNcXBlSzFvelZZZktUaUo0RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T20:55:08+00:00", "published_display": "16 Jul 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNazZnaTl3TmFwNDR3MVdGc3h5eVNtbG82SFFaR2FvWU9iY3VCWlk0d0lVc2Rsb3kzamM0ck52aFhUVVRjc0RvUXlxVnBHd0tRUnlMaGFLbUtyV2c5VG0wV09HaVBQRHJYdE4yZy1ndk9uMFBJRHVwekQzb25DVjNoVGRiQkZDZ2FwTnRENXRSc2pTNERxOUxUMWp3OG0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:13:43+00:00", "published_display": "15 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNZEpjZmI4UEtXd3BETFd3Y0pNeXdIUk5pVW84QjBsX3BmRTFEOW1KcTNBRC1rQTZYLVVsNk50WnpwS2VhMWFBdHZkZFlXcUVNUEREbTNrQkdCSU1KQWZMcHFvZmJWSmRUTjN1bGJ3NEhyN3Y0SGVOZmRRVExnU09DRVp1cjBVRnFIUU5Wd0xEcTNhTmRGQlNVRmlyX2JyOWsyOWVpUnFHNUdrdFNUck92eUZQS1NtSE5SejdsdmpCQ2lBNkY4ZGEwOTNWVG9kU3Aza2xhYQ?oc=5", "source_name": "Reuters", "published_at": "2026-07-14T16:33:43+00:00", "published_display": "14 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences, Inc. (GILD) Stock Analysis: Promising 21.93% Upside Amid Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPLUE4TjFuWVFnYXp6R2NkZlhUblVRRkw5NTRpTGt0ZGhzZnBXQ09ZREFvTndDYTBEeDJveC1zMGk0R09Zb3EyNllpVm9vRmdtM2k2T3ByMy1uNFpTWENNT0p2TmxRcnlmd0E3bEFPbTM1eGN2Z1czNnY3UG0tdTF0ZUdhNXYxMnFkc0NwRVNyMlZENkNac0lvMHgtaGx1YkRjc2dEbmcxN21KNFZ3cHpHTGViOGVjMDIya1lmWkdPa29HaFI5VE5JazVQUi1GUTdESmJF?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:07+00:00", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQclR2UzJHMm1iZG44T2dzUFpGQmh5aDVsYmI2ejZkVFk1amV2Y29QbmFCTEdzQXJvMzYwYzJoY2dvRV96RTJxQkt2dUJCV2pobDN0YnpHTmx5TlA3TnA2ZHdRM29KRkZJRjFxNEk3X3piWGFzU0FhV1ZabkFYcXZPcVNpMlpNYTFaelY5a3BnTkFfM0tBTDBsTmNPdlM?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going on With Gilead Sciences Stock Monday? - Gilead Sciences (NASDAQ:GILD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRldaalhnQUt1cDhNazJyQTBscGN4VmJLamZVbnhXY1p2RVltSzJ6bDAyTjk0R2tsWWJjc2s0eTFVeThTekw1UUFpSDJpWGo1RndUYklEVXdSWEtLb0xMU1RCd01oSmVFTXZlWHhRVUVjUkJLTEVBQnpJS3htN0ZCZkt5R2NoN2NKelI5YkRzZ2VuTmIyRGxPQm5iWnlaZENpZUhWLUFtV2FnVE0zenM0ZG1kdVdaVUtTbjl1UEVUYXI3MWVyY3ZrbGl2dFZ5U1pBUlg4bTZlVQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should First-Line Trodelvy Breast Cancer Approvals Reshape the Gilead Sciences (GILD) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Trodelvy\u2019s First-Line TNBC Approval Redefine Gilead Sciences\u2019 (GILD) Oncology-Led Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQb1Y3U09pU3plcjhBLVR4YnlEWmpXY3dFRHI4NXlnck5mMjN2WTQ3X2IxYVlULUVSVGM2T1lFY2xIb0VqaE9rZ1NkWTBKS3FMTFpReDM5MlBZcEZfQ3lrNUxGNl9nRnBDV2cybE5LTUFJNUdIdklTRVRvbWNobkpkbU1ibDFXVkhGdjEtU2ZhdGJoUFBibldISDBB?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPQk1DTTdDeWFIb0JSZWdIamtYVzlxcnJ5THpBM2lfR0VLQ1lqamRMVS16eThoOUcyZjA3UmpNTkVlVzdsYVJtV04tUy05S1NVQkZ5Q2hMa1NzUDQxUThNcU5Qc1hGSTV3NUs4eEg5azhEX0xyaWJGQm93UmFnejg2bk5UdUM3bGs2bWV6YTZ4WkJRX1RlTFR5QUI1TWNBZFpUZlMxekZYMHY4UmV2YlNHSHM1aTBpdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ3RhTlFnWC1qTkw3YXFtQ0pBSmEtYW8zRGdPUzhJNVhQQjhBUmtlRkszQzJNaGM3MXlYb0tmV0tWWHNscG8yV1pIaXV0NnJLRVhpaF9Ub3NWYWxLOUdhQ2JrSnlkSnBHenloWGsxRUtDaHhReHNkZWVEVTA5di01ZmI3QVRVX09SREwzQkJfSUJVNGNEM1lrUVRsR3hrdw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead's drug wins first-ever US approval for deadly liver infection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOY1U3aGJZNU9NX1FZVUQtSm1PR1JCdnktUFNKa0JNak4zTHBaQ1NwckZwWUg4ZHFnNWlac0xGVUNtRVVMNmdSWUJmbUV4b3l2ZkRWeEJ2OV9ubThfN2F2Vjd6MWhsU1VkV09GMDFSUk5jTlMyVGRmSWNmTUMxc3Z3OVpGelcwZ1pFRWlfQUM0d3FTV0xIQnMzcklOOGZldWZ4ZlFTelRSZjVMTjhRaVhaWi1zbmJOT0ppQWxrbjFGcFI?oc=5", "source_name": "Reuters", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNeV9feXBaekdJMVZzOEdEQzByUG1UTW0wdFRNYnhvOUxyWXR3ZDNIWWZrbmlCVEJXYWtFS1hXZndLT1g1VFVJVHlyNmNBZ0VXVVhKYVMzd2t1NS05dVZBbGcwVHI1b3NaRk5ZOEhoMW1yeTdxdWNhR0FrWFpmUUlOcHg3UkJmMUJDSHl1bW0yWWk1cm9tZmNCb21KUGo3NENP?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Just Told Investors What to Watch Before December 23. Here\u2019s What the Data Says About GILD Stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMy1FZks3blJfcHlFUXMxclRvdWtELUZ1Vk80amFiMlJKUGdIamE3UjJmX3JmOXpUN2ZTRXBEWm5JdF9KejJXMW5DZ1k5MDlydTZUdkVxUlVUQ1JIN3I0WVowTlRRS1dscGtKOC1tQjNLZjd5dGNEanZweFp3UUsxc193blRFZjR2WjFMTVBvbUc1NS1Td29wZ0U2azEwR3IwZTdlMk9IdUhVWllacHFmVl9lR2RJNThRbWhEMjZIV2x2RUpieW83VE4xTE1mb0dmb0E?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMS1kN2xmaTh4MTlPODdvOE12di05bS1RbFhpNHg2dDJGSXlZYXV1T2MzNEYzZUMwQnB2YWZVNnZEdE51SjdFdE1nSDRRajh3Xzd4V2x1Smc1NTVFUG0xQlBjRU1ZbWUtUWE2VG03VUx2dXE0Unk1R2Nfc0VVRkFpZkh2LVZZQmlTM1lBem5xYWxVeFNUYnlCbkNIdEdEQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSVFlVWF4b3BsZlAtbGZmaWFxVXRfQ0V4Z0F5elpteGYzWHhvWWpxV2lKejRmTkItNDF3SDlTcXdidm1qeTRNeEU1Vl9hUGdXWlp0MVpySlFoQlVXbTFQalVWdTU3Uld1SHUxZ212MGZmakVDSUZHNmREZmN0N2IyY1FLWFNzVXFQVG1JVWM2YlFQTEtpNkNYbjg5d0JiNUp2YkYyd180dktEUQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead to Buy Cancer Biotech Tubulis in $5 Billion Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNUVlVb3FPNFFkSkFlb2puclNiRTZ3SDkwRDRTanVfNzA4alFzNlJLTEFCWWpJX1ZwYklSLW95ci1oUFFwSktOSndRdEVIUGJrZklldlVqN2kzb1hfRzFOQzZJVDR3X01qTXdzMUY0aXBEMXVuRVJLUExJaFY3Smw1TXkzUXk1ZUk5MHk0eFJyQ1JYM0JIc2ctOEpmN0JhbjdVVHF4Z0Q0NHNUbXNHcFNmcXNn?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead posts higher profit on demand for HIV drugs, but overall sales dip", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOcm1McnpwdXpIeENNSDlNVHlwNDFzNHBndWhzVXoyaDFacXloLXpjV2pqbTUwckJ2T18wZzN3ZFhWRmZvaXh1N1pLc2F0NGJablRHVlFTdWhWX3hFNld2N1Roa3h4aUl2MWptYjltRFlYWjZXMjZpTmdnVi04bjNXNHdkSzRvME9qbVFfd01va3ZKQXpXWTRQa1RUV0tVYVlXaXZrM2JoT2FQZERPTjlwQnVTZDNmNnRGZFl5cUlaUTRSVXpMdllkVHZ6aUFnZUhoQU9ocUc0cw?oc=5", "source_name": "Reuters", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Gilead's twice-yearly injection for HIV prevention", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNMlA0ZVVHb09YYjZsMzFGLVlWR3ptNWwwM3ZaZVdUd3FiWm1QV1hTWVNDXzZ6dno4QWluT3ZSM2g1WFdpX2ZUYUdvM0N1SVJqb3VIUVR5T19lZlFKbFlMZEk1QXR4ajEzSVZ4NGp1cWx3S0dEY1BJTzVDOWJLM3ZWc2RxZVB6VWZfcG1SS05Fc2VORDNFMlpCblBCU1VERUZZVjZCZEtSMzhJLXNtcEtUWWwtd1FCXy0xUlNPOElUSWtfT0I2Z3ROVU1VMWFhdw?oc=5", "source_name": "Reuters", "published_at": "2025-06-18T07:00:00+00:00", "published_display": "18 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Gilead's drug lenacapavir have the power to end the AIDS epidemic? - San Francisco Business Times", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNYzd6YXdmVUZrTVdjVWcyVjhoRGJLdjkwcnB0NWdwVnp5bnhCbkpULXZZZFRBTDV2ZVpoMFM2bU1xUVJKeE9Pbm9mMzVUZW5BdmRQdDNjdUkxWDJJTmFDakZjTWxaSTR4amN2a1JRQXctNE5pYUZ6YVZlMWRtbUxkeVIta3VhdHlsbFdHWWhUV2Fad1ltNEFfV01SSkNmOWs?oc=5", "source_name": "The Business Journals", "published_at": "2025-05-15T07:00:00+00:00", "published_display": "15 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GILEAD SCIENCES APPOINTS PAUL PETRELLI TO VICE PRESIDENT AND GENERAL MANAGER IN CANADA", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxONm5PVmQ2Zjl1MjdabUlSMVE2NDFUTUI0bnpCNWxXUkN2N2ROb0dVbFotNnBwelRhYnlaYTdVeTZDWUFkaU0wZWJQRVpKTjhPbnhmRUlzTFBzOXg5RER5Rl90YV9NN21oUlNDY3hZb2ZleFRrQUQyUXlIN3F2ZnJMN1psMnBIZ2l2NFM5Y2t6U0hNMjZ0Tm12ekxhTmQ0d2h0QkNEeDlqdm85ZHBZZ0xxMHM3X1M2YVBZazEyYUZQYVVZVnZJOGtEVG11TkhwNnp1SVJfMHlB?oc=5", "source_name": "PR Newswire Canada", "published_at": "2024-11-07T08:00:00+00:00", "published_display": "07 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead and HRC launch $5M initiative to end HIV epidemic by 2030", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxPTUNzWDcyd09HVDMtbm5QMnVLT2h4TkZNaDVKMm9XMF84RzNYc2xHU0ZPV0ZrVVZRc1A1a3hnWkM0cnE2MTFQdGlmdVJ1b1BUWTFJSTRwMWhWSGlaeThrNkdPNUZ2b2RadU9fUXpPMTc1ZEFVaVpXUW5kSFNKMU50X19PMU5OTGJfaVdwNk43V1RvNTB4RUs2eGZBQXdSazl6SF8zaUhBbXloLVFQbzRQRGE0R3JKZTBxR1BIdm40VWFSUmZST2tiRl9uV2VuWWNNZV9kekY3S2E2MFVOZ3FRcWw3UFFVdzFxRngzc21Yc0VZZUZ2UGlaMUVtWnJBb2F3UmtiRFlWZURSUG9hY3JnTjZnMEZqLXFib1FSa3FRV2cxOEFhWk9DZUtTd2x1eC03OHdVLVB3?oc=5", "source_name": "HRC | Human Rights Campaign", "published_at": "2023-05-31T07:00:00+00:00", "published_display": "31 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPQUJHZEY1bTg5bXB1UG5xU3lwV2lyYTlKTWFGUktTM3FXUFYxZVhxTjd5cGxMaXFPQWw1X2lsZXRobUp5R3hsLXk2UkJMZ3ZSaVdpUEMyazFXUTN1TURweXlEeUpVWmtWUFFBaWlCYmFuWE5CLThIa3JIYldKbDBiUmhjSG4wdw?oc=5", "source_name": "Los Angeles Times", "published_at": "2017-08-28T07:00:00+00:00", "published_display": "28 Aug 2017 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead shares plunge after Express Scripts spurns its $1,000 hepatitis C pill", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPNXN5UnBQSzdYUEZfZE5YaV9tcmItR1R3aXdWQTlrSXpoXy1IMkg3aFpsczI5VVUwQV9ST201YVUwOU1yVlVrRjYtWHgybVV2S1NTYXZLVm9ucE03QXZuMnM0WHdvMnpTZmNLWFczMG40RmFUZnVxSFl6T1FtWFZwbUpIZHNITV9RcGc?oc=5", "source_name": "Los Angeles Times", "published_at": "2014-12-22T08:00:00+00:00", "published_display": "22 Dec 2014 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Gilead (GILD) Stock Could Still Trade At A Discount Following Its 127% Run", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-22T08:27:46+00:00", "published_display": "22 Jul 2026 08:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead sets Aug. 4 webcast to discuss second-quarter results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOcTY5bXFhQVlYY1ZzSms0SjBvR19UT3hnMHdsQ2piN0EySDYwdTl5ekUtdEJoV3JaZTRsMlRRODloMk5YMVVnR21PTFNoVEY2V251clJsOHk0QmlDNmk1VFd4YTZ5MHowZ29sUl8tMEhQd0RlMmpTcDFRcUJkRkVYdWJ1NDdra3FfaXZlQ1RYN0k2cVhhallHZUQ0enV5cXZaNXZiVWVzRTJaS205OXMtLWJ6cFdIcTRrNm93TGhzUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T20:05:00+00:00", "published_display": "21 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences' Quarterly Earnings Preview: What You Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUUVFdUhNc042MDJaendBLWNVOTk3enR6RUd3cXYyREpoT1ZrRVNOX3F2MGtBbnhabG4ydkFpaFZLMkV1WW4yM1JMdVhfdmJCLThiVTA2dDU2THM3QmcxanpqQXJWNDMyVjdXQlZ4VXJrTzdLbUJFOTMyZWRmMGhEY1BUZXpBRVlZOF9DdUZsUzc0cTdJVmk3TE1MTENMSm9v?oc=5", "source_name": "inkl", "published_at": "2026-07-21T12:56:06+00:00", "published_display": "21 Jul 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxObUJabGVPbXJTRnMycU9vSmp1Q0RCZExIZUNPbUhMbno0QW1tTllEYnNoOU1KS3k5TGFNYlc0RU5EMlRYMGpKbFRFUHdnQzFaX0prLWxJTHduRldEYnkzeDRUd25DZjRlS3o1Z19JcElPemNQamNTSl9FRDdEUFo2Y0tqQlNDaGFJWS16OUZQVjJyeWZncjlOM1gxNUpSQnJuMkNEc0JvdDRndmVZTThoLXpNOXE3ejNIb1dV?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T21:35:27+00:00", "published_display": "16 Jul 2026 21:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZFYxNFltWHNNWXR0X0djdnRuVmRIV1IxLVdpRUpBOUZkZUZkNkkzQUJpZVAyVXFmNy1sRVVBdnpQWDlrTlNyZXZiaElvOHZuYjFuNHZnM1V0SUFqal9VNTNUX0kwZWx3b0JiOF9HVUpSS2J4WXZES3RWd0dOVHlhT3l4U3AxbVZIWWppeXVCUlhhYTZLUkpLV3V5SkY5UERINnFNcXBlSzFvelZZZktUaUo0RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T20:55:08+00:00", "published_display": "16 Jul 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNazZnaTl3TmFwNDR3MVdGc3h5eVNtbG82SFFaR2FvWU9iY3VCWlk0d0lVc2Rsb3kzamM0ck52aFhUVVRjc0RvUXlxVnBHd0tRUnlMaGFLbUtyV2c5VG0wV09HaVBQRHJYdE4yZy1ndk9uMFBJRHVwekQzb25DVjNoVGRiQkZDZ2FwTnRENXRSc2pTNERxOUxUMWp3OG0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:13:43+00:00", "published_display": "15 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNZEpjZmI4UEtXd3BETFd3Y0pNeXdIUk5pVW84QjBsX3BmRTFEOW1KcTNBRC1rQTZYLVVsNk50WnpwS2VhMWFBdHZkZFlXcUVNUEREbTNrQkdCSU1KQWZMcHFvZmJWSmRUTjN1bGJ3NEhyN3Y0SGVOZmRRVExnU09DRVp1cjBVRnFIUU5Wd0xEcTNhTmRGQlNVRmlyX2JyOWsyOWVpUnFHNUdrdFNUck92eUZQS1NtSE5SejdsdmpCQ2lBNkY4ZGEwOTNWVG9kU3Aza2xhYQ?oc=5", "source_name": "Reuters", "published_at": "2026-07-14T16:33:43+00:00", "published_display": "14 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences, Inc. (GILD) Stock Analysis: Promising 21.93% Upside Amid Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPLUE4TjFuWVFnYXp6R2NkZlhUblVRRkw5NTRpTGt0ZGhzZnBXQ09ZREFvTndDYTBEeDJveC1zMGk0R09Zb3EyNllpVm9vRmdtM2k2T3ByMy1uNFpTWENNT0p2TmxRcnlmd0E3bEFPbTM1eGN2Z1czNnY3UG0tdTF0ZUdhNXYxMnFkc0NwRVNyMlZENkNac0lvMHgtaGx1YkRjc2dEbmcxN21KNFZ3cHpHTGViOGVjMDIya1lmWkdPa29HaFI5VE5JazVQUi1GUTdESmJF?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:07+00:00", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQclR2UzJHMm1iZG44T2dzUFpGQmh5aDVsYmI2ejZkVFk1amV2Y29QbmFCTEdzQXJvMzYwYzJoY2dvRV96RTJxQkt2dUJCV2pobDN0YnpHTmx5TlA3TnA2ZHdRM29KRkZJRjFxNEk3X3piWGFzU0FhV1ZabkFYcXZPcVNpMlpNYTFaelY5a3BnTkFfM0tBTDBsTmNPdlM?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going on With Gilead Sciences Stock Monday? - Gilead Sciences (NASDAQ:GILD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRldaalhnQUt1cDhNazJyQTBscGN4VmJLamZVbnhXY1p2RVltSzJ6bDAyTjk0R2tsWWJjc2s0eTFVeThTekw1UUFpSDJpWGo1RndUYklEVXdSWEtLb0xMU1RCd01oSmVFTXZlWHhRVUVjUkJLTEVBQnpJS3htN0ZCZkt5R2NoN2NKelI5YkRzZ2VuTmIyRGxPQm5iWnlaZENpZUhWLUFtV2FnVE0zenM0ZG1kdVdaVUtTbjl1UEVUYXI3MWVyY3ZrbGl2dFZ5U1pBUlg4bTZlVQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should First-Line Trodelvy Breast Cancer Approvals Reshape the Gilead Sciences (GILD) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Trodelvy\u2019s First-Line TNBC Approval Redefine Gilead Sciences\u2019 (GILD) Oncology-Led Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQb1Y3U09pU3plcjhBLVR4YnlEWmpXY3dFRHI4NXlnck5mMjN2WTQ3X2IxYVlULUVSVGM2T1lFY2xIb0VqaE9rZ1NkWTBKS3FMTFpReDM5MlBZcEZfQ3lrNUxGNl9nRnBDV2cybE5LTUFJNUdIdklTRVRvbWNobkpkbU1ibDFXVkhGdjEtU2ZhdGJoUFBibldISDBB?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPQk1DTTdDeWFIb0JSZWdIamtYVzlxcnJ5THpBM2lfR0VLQ1lqamRMVS16eThoOUcyZjA3UmpNTkVlVzdsYVJtV04tUy05S1NVQkZ5Q2hMa1NzUDQxUThNcU5Qc1hGSTV3NUs4eEg5azhEX0xyaWJGQm93UmFnejg2bk5UdUM3bGs2bWV6YTZ4WkJRX1RlTFR5QUI1TWNBZFpUZlMxekZYMHY4UmV2YlNHSHM1aTBpdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ3RhTlFnWC1qTkw3YXFtQ0pBSmEtYW8zRGdPUzhJNVhQQjhBUmtlRkszQzJNaGM3MXlYb0tmV0tWWHNscG8yV1pIaXV0NnJLRVhpaF9Ub3NWYWxLOUdhQ2JrSnlkSnBHenloWGsxRUtDaHhReHNkZWVEVTA5di01ZmI3QVRVX09SREwzQkJfSUJVNGNEM1lrUVRsR3hrdw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead's drug wins first-ever US approval for deadly liver infection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOY1U3aGJZNU9NX1FZVUQtSm1PR1JCdnktUFNKa0JNak4zTHBaQ1NwckZwWUg4ZHFnNWlac0xGVUNtRVVMNmdSWUJmbUV4b3l2ZkRWeEJ2OV9ubThfN2F2Vjd6MWhsU1VkV09GMDFSUk5jTlMyVGRmSWNmTUMxc3Z3OVpGelcwZ1pFRWlfQUM0d3FTV0xIQnMzcklOOGZldWZ4ZlFTelRSZjVMTjhRaVhaWi1zbmJOT0ppQWxrbjFGcFI?oc=5", "source_name": "Reuters", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNeV9feXBaekdJMVZzOEdEQzByUG1UTW0wdFRNYnhvOUxyWXR3ZDNIWWZrbmlCVEJXYWtFS1hXZndLT1g1VFVJVHlyNmNBZ0VXVVhKYVMzd2t1NS05dVZBbGcwVHI1b3NaRk5ZOEhoMW1yeTdxdWNhR0FrWFpmUUlOcHg3UkJmMUJDSHl1bW0yWWk1cm9tZmNCb21KUGo3NENP?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Just Told Investors What to Watch Before December 23. Here\u2019s What the Data Says About GILD Stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMy1FZks3blJfcHlFUXMxclRvdWtELUZ1Vk80amFiMlJKUGdIamE3UjJmX3JmOXpUN2ZTRXBEWm5JdF9KejJXMW5DZ1k5MDlydTZUdkVxUlVUQ1JIN3I0WVowTlRRS1dscGtKOC1tQjNLZjd5dGNEanZweFp3UUsxc193blRFZjR2WjFMTVBvbUc1NS1Td29wZ0U2azEwR3IwZTdlMk9IdUhVWllacHFmVl9lR2RJNThRbWhEMjZIV2x2RUpieW83VE4xTE1mb0dmb0E?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMS1kN2xmaTh4MTlPODdvOE12di05bS1RbFhpNHg2dDJGSXlZYXV1T2MzNEYzZUMwQnB2YWZVNnZEdE51SjdFdE1nSDRRajh3Xzd4V2x1Smc1NTVFUG0xQlBjRU1ZbWUtUWE2VG03VUx2dXE0Unk1R2Nfc0VVRkFpZkh2LVZZQmlTM1lBem5xYWxVeFNUYnlCbkNIdEdEQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSVFlVWF4b3BsZlAtbGZmaWFxVXRfQ0V4Z0F5elpteGYzWHhvWWpxV2lKejRmTkItNDF3SDlTcXdidm1qeTRNeEU1Vl9hUGdXWlp0MVpySlFoQlVXbTFQalVWdTU3Uld1SHUxZ212MGZmakVDSUZHNmREZmN0N2IyY1FLWFNzVXFQVG1JVWM2YlFQTEtpNkNYbjg5d0JiNUp2YkYyd180dktEUQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead to Buy Cancer Biotech Tubulis in $5 Billion Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNUVlVb3FPNFFkSkFlb2puclNiRTZ3SDkwRDRTanVfNzA4alFzNlJLTEFCWWpJX1ZwYklSLW95ci1oUFFwSktOSndRdEVIUGJrZklldlVqN2kzb1hfRzFOQzZJVDR3X01qTXdzMUY0aXBEMXVuRVJLUExJaFY3Smw1TXkzUXk1ZUk5MHk0eFJyQ1JYM0JIc2ctOEpmN0JhbjdVVHF4Z0Q0NHNUbXNHcFNmcXNn?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead posts higher profit on demand for HIV drugs, but overall sales dip", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOcm1McnpwdXpIeENNSDlNVHlwNDFzNHBndWhzVXoyaDFacXloLXpjV2pqbTUwckJ2T18wZzN3ZFhWRmZvaXh1N1pLc2F0NGJablRHVlFTdWhWX3hFNld2N1Roa3h4aUl2MWptYjltRFlYWjZXMjZpTmdnVi04bjNXNHdkSzRvME9qbVFfd01va3ZKQXpXWTRQa1RUV0tVYVlXaXZrM2JoT2FQZERPTjlwQnVTZDNmNnRGZFl5cUlaUTRSVXpMdllkVHZ6aUFnZUhoQU9ocUc0cw?oc=5", "source_name": "Reuters", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Gilead's twice-yearly injection for HIV prevention", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNMlA0ZVVHb09YYjZsMzFGLVlWR3ptNWwwM3ZaZVdUd3FiWm1QV1hTWVNDXzZ6dno4QWluT3ZSM2g1WFdpX2ZUYUdvM0N1SVJqb3VIUVR5T19lZlFKbFlMZEk1QXR4ajEzSVZ4NGp1cWx3S0dEY1BJTzVDOWJLM3ZWc2RxZVB6VWZfcG1SS05Fc2VORDNFMlpCblBCU1VERUZZVjZCZEtSMzhJLXNtcEtUWWwtd1FCXy0xUlNPOElUSWtfT0I2Z3ROVU1VMWFhdw?oc=5", "source_name": "Reuters", "published_at": "2025-06-18T07:00:00+00:00", "published_display": "18 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Gilead's drug lenacapavir have the power to end the AIDS epidemic? - San Francisco Business Times", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNYzd6YXdmVUZrTVdjVWcyVjhoRGJLdjkwcnB0NWdwVnp5bnhCbkpULXZZZFRBTDV2ZVpoMFM2bU1xUVJKeE9Pbm9mMzVUZW5BdmRQdDNjdUkxWDJJTmFDakZjTWxaSTR4amN2a1JRQXctNE5pYUZ6YVZlMWRtbUxkeVIta3VhdHlsbFdHWWhUV2Fad1ltNEFfV01SSkNmOWs?oc=5", "source_name": "The Business Journals", "published_at": "2025-05-15T07:00:00+00:00", "published_display": "15 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GILEAD SCIENCES APPOINTS PAUL PETRELLI TO VICE PRESIDENT AND GENERAL MANAGER IN CANADA", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxONm5PVmQ2Zjl1MjdabUlSMVE2NDFUTUI0bnpCNWxXUkN2N2ROb0dVbFotNnBwelRhYnlaYTdVeTZDWUFkaU0wZWJQRVpKTjhPbnhmRUlzTFBzOXg5RER5Rl90YV9NN21oUlNDY3hZb2ZleFRrQUQyUXlIN3F2ZnJMN1psMnBIZ2l2NFM5Y2t6U0hNMjZ0Tm12ekxhTmQ0d2h0QkNEeDlqdm85ZHBZZ0xxMHM3X1M2YVBZazEyYUZQYVVZVnZJOGtEVG11TkhwNnp1SVJfMHlB?oc=5", "source_name": "PR Newswire Canada", "published_at": "2024-11-07T08:00:00+00:00", "published_display": "07 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead and HRC launch $5M initiative to end HIV epidemic by 2030", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxPTUNzWDcyd09HVDMtbm5QMnVLT2h4TkZNaDVKMm9XMF84RzNYc2xHU0ZPV0ZrVVZRc1A1a3hnWkM0cnE2MTFQdGlmdVJ1b1BUWTFJSTRwMWhWSGlaeThrNkdPNUZ2b2RadU9fUXpPMTc1ZEFVaVpXUW5kSFNKMU50X19PMU5OTGJfaVdwNk43V1RvNTB4RUs2eGZBQXdSazl6SF8zaUhBbXloLVFQbzRQRGE0R3JKZTBxR1BIdm40VWFSUmZST2tiRl9uV2VuWWNNZV9kekY3S2E2MFVOZ3FRcWw3UFFVdzFxRngzc21Yc0VZZUZ2UGlaMUVtWnJBb2F3UmtiRFlWZURSUG9hY3JnTjZnMEZqLXFib1FSa3FRV2cxOEFhWk9DZUtTd2x1eC03OHdVLVB3?oc=5", "source_name": "HRC | Human Rights Campaign", "published_at": "2023-05-31T07:00:00+00:00", "published_display": "31 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPQUJHZEY1bTg5bXB1UG5xU3lwV2lyYTlKTWFGUktTM3FXUFYxZVhxTjd5cGxMaXFPQWw1X2lsZXRobUp5R3hsLXk2UkJMZ3ZSaVdpUEMyazFXUTN1TURweXlEeUpVWmtWUFFBaWlCYmFuWE5CLThIa3JIYldKbDBiUmhjSG4wdw?oc=5", "source_name": "Los Angeles Times", "published_at": "2017-08-28T07:00:00+00:00", "published_display": "28 Aug 2017 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead shares plunge after Express Scripts spurns its $1,000 hepatitis C pill", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPNXN5UnBQSzdYUEZfZE5YaV9tcmItR1R3aXdWQTlrSXpoXy1IMkg3aFpsczI5VVUwQV9ST201YVUwOU1yVlVrRjYtWHgybVV2S1NTYXZLVm9ucE03QXZuMnM0WHdvMnpTZmNLWFczMG40RmFUZnVxSFl6T1FtWFZwbUpIZHNITV9RcGc?oc=5", "source_name": "Los Angeles Times", "published_at": "2014-12-22T08:00:00+00:00", "published_display": "22 Dec 2014 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 89, "total_relevant": 28, "sentiment_summary": {"positive": 5, "negative": 1, "neutral": 22, "score": 54, "total": 28, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 12.25, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 2.55, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.45, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.9, "count": 1}], "positive_events": 5, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 2400.0, "latest_week": "2026-07-17", "one_week_move": 5.5, "four_week_move": 13.4, "twelve_week_move": 3.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.462413, "market_dynamics_buy_signal": false, "relative_strength": 2.498703, "fair_value_gap": 32.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.3231, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.5% over one week, +13.4% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 5}, {"label": "Reuters", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "TIKR.com", "count": 2}, {"label": "Los Angeles Times", "count": 2}, {"label": "inkl", "count": 1}, {"label": "GuruFocus", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 28}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "28", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.5% over one week, +13.4% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Gilead (GILD) Stock Could Still Trade At A Discount Following Its 127% Run"}], "updated_at": "2026-07-22T20:40:18.192596+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}